Chairs: S. Bielack, DE - B. Morland, UK - C. Stefan, RO/ZA
Host Chair: M. Dragomir, RO
ESO and SIOP-Europe are pleased to announce the eighth Masterclass in Paediatric Oncology. This clinically-oriented educational programme has been designed for young paediatric oncologists, who wish to improve their skills in clinical management of common childhood tumours. It is designed to offer a unique learning experience, providing practice-oriented training and the teaching sessions will focus on the application of the most recent research findings to clinical practice.
• Improve knowledge in the field
• Improve skills in dealing with cancer problems as a whole
• Improve knowledge of current clinical practice and state-of-the-art treatment
• Bone tumours
• Central nervous system tumours
• Rare tumours
• Soft-tissue sarcoma
• Wilms’ tumour
A. Attarbashi, St. Anna’s Kinderspital, Vienna, AT
S. Bielack, Olgahospital, Dept. of Oncology, Stuttgart, DE
G. Bisogno, Onco-Haematology Clinic, Department of Paediatrics, Padova, IT
F. Doz, Institut Curie, Paediatric Oncology Dpt., Paris, FR
A. Eggert, Charité - Berlin University, Department of Paediatric Oncology/ Haematology, Berlin, DE
J. Grill, Institut Gustave Roussy, Department of Pediatrics, Villejuif, FR
H. Hasle, Aarhus University Hospital, Aarhus, DK
A. Hoy, Consultant in Palliative Medicine, Epsom, UK
D. Körholz, Universitätsklinikum, Halle, Halle, DE
B. Morland, Birmingham Childrens’ Hospital, Birmingham, UK
D. Orbach, Institut Curie, Paediatric Department, Paris, FR
D. Schneider, Klinikum Dortmund, Children’s Department, Dortmund, DE
M. Schrappe, University of Kiel, Department of Paediatrics, Kiel, DE
T. Simon, University Clinic Köln, Pediatric Oncology/Hematology Dpt., Köln, DE
R. Skinner, Great North Children's Hospital, Newcastle upon Tyne, UK
F. Spreafico, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT
European School of Oncology (ESO)
Piazza Indipendenza 2
ph +41 91 820 09 54
Dolores Knupfer, firstname.lastname@example.org, ph: +41 91 820 0952
CME ACCREDITATION AND CERTIFICATE
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and to the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS).
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising secretariat.
Participants will receive their certificate of attendance via e-mail after on completion of the evaluation form.
• Age between 30 and 40 years
• 2-4 years’ experience in paediatric oncology
• Involvement in scientific activities and clinical trials
• Fluency in English
Admittance to the Masterclass is by competitive application. The successful applicants are granted free registration but the cost of half-board accommodation and transfer to the course venue is EUR 450.- for the period 6-11 June 2020 and travel will be covered by the participants.
All participants will be expected to reside at the course venue and their full participation is compulsory throughout the course.
The Masterclass will be taught entirely in English and fluency in English is necessary for admission.
Four full tuition scholarships will be offered to applicants from Low and Middle Income Countries (LMIC) as defined by the World Bank. In order to be considered for a scholarship, please submit a letter of motivation requesting consideration. Please note that scholarship recipients will be responsible for arranging their own travel to Bucharest.
HOW TO APPLY
Interested oncologists should apply online (at the top of this page) providing:
• Letter describing motivation for attending the Masterclass
• Short CV (maximum 2 pages) describing recent clinical experience and list of any recent
• Supporting letter from Head of Department/Mentor
• Abstract with proposed presentation of a clinical case relating to one of the main themes of the Masterclass (bone tumours, central nervous system tumours, leukemia, lymphoma, neuroblastoma, rare tumours, soft-tissue sarcoma or Wilms’ tumour)
The abstract should be presented in the form of a grand-round clinical discussion rather than a publication report, and describe:
• Diagnostic considerations
• Outcome (follow-up)
• Up to three questions that the author proposes for discussion by the faculty and participants
Candidates should avoid the selection of very rare or unusual cases and try to find learning points from clinical situations more likely to be encountered in day to day practice.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
APPLICATION DEADLINE: 12 FEBRUARY 2020
Before you start completing the online application form, please be sure you have all the requested files (CV, Motivation letter, Supporting letter, Professional experience template and Abstract template) ready to be uploaded to the system. Online applications will not be complete unless all the files are uploaded.
• Download HERE your Professional experience template
• Download HERE your Abstract template
|20:00||Welcome from the Chairs followed by dinner|
|8:30||Multiple choice pre-test|
S. Bielack, DE
|9:00||Bone sarcomas/case presentations|
|11:15||Bone sarcomas/case presentations
B. Morland, UK
|8:00||Intracranial Germ Cell Tumours
|8:30||Germ Cell Tumours
|11:30||Key note lecture: T-cells
|Management of AML|
|20:00||Offsite dinner, Caru' cu Bere|
|8:00||Communication workshop (RED GROUP)
|9:00||Key note lecture: Early phase studies (BLUE GROUP)
B. Morland, UK
|SOFT TISSUE SARCOMA
|11:30||Non Rhabdo Soft Tissue Sarcoma
|12:30||Questions and discussion
|16:30||Communication workshop (BLUE GROUP)|
|16:30||Key note lecture: Early phase studies (RED GROUP)
|8:00||Overview: Non-Hodgkin's Lymphoma
A. Attarbaschi, AT
|9:00||Overview: Hodgkin's Lymphoma|
|14:00||Keynote lecture: How to identify patients who may benefit from personalised medicine
|15:00||Current approaches in low risk and intermediate risk neuroblastoma
T. Simon, DE
|16:30||Current approaches in high-risk and relapse neuroblastoma|
|8:00||Overview of renal tumours of childhood and approaches to treatment of Wilms tumour (part I)|
|9:30||Overview of renal tumours of childhood and approaches to treatment of Wilms tumour (part II)
|12:15||Multiple choice test
|12:45||Discussion and closure|
|13:30||Group transfer from hotel to airport|